cxxc5-dvl

KY-02327, a metabolically stabilized analog of KY-02061, serves as a potent inhibitor of the Dishevelled (Dvl)-CXXC5 interaction. This compound activates the Wnt/β-catenin pathway, thereby promoting osteoblast differentiation.

KY19382 (2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro-Ky19382) is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β( IC50s of 19 and 10 nM, respectively). It activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity. KY19382 can be used for the research of high fat diet (HFD) induced metabolic diseases.

A3051, is a robust and orally active inhibitor of CXXC5-DVL with an IC 50 of 63.06 nM. Its applications include research into phenotypes associated with obesity, diabetes, and NASH that are induced by high fat diet (HFD) and methionine-choline deficient diet (MCD).

KY19334 is an inhibitor of CXXC5-DVL. By blocking the interaction between CXXC5 and Dvl, KY19334 activates the Wnt/β-catenin signaling pathway. It also hinders the proliferation, migration, invasion, and transformation of cancer cells through CDK1 inhibition. Moreover, KY19334 accelerates wound healing and promotes regeneration. This compound is applicable in research related to cancer, inflammation, neurological, and metabolic disorders, such as skin squamous cell carcinoma and diabetes.

KY-02327 acetate is a potent inhibitor of Dishevelled (Dvl)-CXXC5 interactions and is a metabolically stable analog of KY-02061. KY-02327 acetate activates the Wnt/β-catenin pathway, which in turn promotes osteoblast differentiation.

PTD-DBM is a competitive peptide that blocks the interaction between CXXC5 and Dvl, thereby inducing the expression of β-catenin, α-SMA, and type I collagen. Additionally, PTD-DBM promotes skin wound healing activity.